The estimated Net Worth of Charles A Jr Rowland is at least $46.8 Million dollars as of 1 December 2023. Mr. Rowland owns over 342,960 units of Blueprint Medicines Corp stock worth over $46,288,566 and over the last 8 years he sold BPMC stock worth over $2,462. In addition, he makes $466,004 as Independent Director at Blueprint Medicines Corp.
Sign up
Mr. Rowland BPMC stock SEC Form 4 insiders trading
Charles has made over 15 trades of the Blueprint Medicines Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 342,960 units of BPMC stock worth $476,714 on 1 December 2023.
The largest trade he's ever made was buying 342,960 units of Blueprint Medicines Corp stock on 1 December 2023 worth over $476,714. On average, Charles trades about 14,140 units every 44 days since 2016. As of 1 December 2023 he still owns at least 534,757 units of Blueprint Medicines Corp stock.
You can see the complete history of Mr. Rowland stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Rowland biography
Charles A. Rowland Jr. serves as Independent Director of the Company. He has served as a member of our board of directors since March 2015. From April 2016 to February 2017, Mr. Rowland served as president and chief executive officer of Aurinia Pharmaceuticals Inc., or Aurinia, and as a member of the board of directors of Aurinia from July 2014 to February 2017. Mr. Rowland previously served as vice president and chief financial officer of ViroPharma Incorporated, or ViroPharma, an international biopharmaceutical company, from October 2008 until it was acquired by Shire plc in January 2014. Prior to joining ViroPharma, from 2006 to 2008, Mr. Rowland served as executive vice president and chief financial officer, as well as the interim co-chief executive officer, for Endo Pharmaceuticals Inc., a specialty pharmaceutical company with a primary focus in pain management. Mr. Rowland previously held positions of increasing responsibility at the following biopharmaceutical companies: Biovail Pharmaceuticals, Inc., Breakaway Technologies, Inc., Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co. Mr. Rowland has served as a member of the board of directors and chairman of the audit committee and compensation committee of Orchard Therapeutics plc since June 2018, as a member of the board of directors, chairman of the compensation committee and member of the audit committee of Viking Therapeutics, Inc. since July 2017 and as a member of the board of directors and chairman of the audit committee and compensation committee of Nabriva Therapeutics, AG, a biotechnology company based in Dublin, Ireland, since January 2015. In addition, Mr. Rowland currently serves on the board of directors and as chairman of the audit committee of Generation Bio, a privately held biopharmaceutical company. Mr. Rowland served as a member of the board of directors and audit committee of Idenix Pharmaceuticals, Inc., a biopharmaceutical company, from June 2013 it was acquired by Merck & Co., Inc. in August 2014.
What is the salary of Charles Rowland?
As the Independent Director of Blueprint Medicines Corp, the total compensation of Charles Rowland at Blueprint Medicines Corp is $466,004. There are 17 executives at Blueprint Medicines Corp getting paid more, with Jeffrey Albers having the highest compensation of $9,362,370.
How old is Charles Rowland?
Charles Rowland is 61, he's been the Independent Director of Blueprint Medicines Corp since 2015. There are 4 older and 24 younger executives at Blueprint Medicines Corp. The oldest executive at Blueprint Medicines Corp is Mark Goldberg, 65, who is the Independent Director.
What's Charles Rowland's mailing address?
Charles's mailing address filed with the SEC is C/O GENERATION BIO CO., 301 BINNEY ST, , CAMBRIDGE, MA, 02142.
Insiders trading at Blueprint Medicines Corp
Over the last 10 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr, and Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.
What does Blueprint Medicines Corp do?
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
What does Blueprint Medicines Corp's logo look like?
Complete history of Mr. Rowland stock trades at Blueprint Medicines Corp, Nabriva Therapeutics Plc, Viking Therapeutics Inc, Orchard Therapeutics plc, and Generation Bio Co
Blueprint Medicines Corp executives and stock owners
Blueprint Medicines Corp executives and other stock owners filed with the SEC include:
-
Jeffrey Albers,
Chief Executive Officer, Director -
Christina Rossi,
Chief Commercial Officer -
Christopher Murray,
Senior Vice President, Technical Operations -
Kathryn Haviland,
Chief Operating Officer -
Tracey McCain,
Chief Legal Officer, Chief Compliance Officer -
Marion Dorsch,
Chief Scientific Officer -
Anthony Boral,
Chief Medical Officer -
Michael Landsittel,
Chief Financial Officer -
Jeffrey W. Albers J.D., M.B.A., MBA,
Chairman, CEO & Pres -
Jeffrey W. Albers M.B.A., J.D., MBA,
CEO, Pres & Director -
Kathryn Haviland,
Chief Operating Officer -
Tracey L. McCain Esq.,
Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec. -
Dr. Fouad Namouni M.D.,
Pres of R&D -
Tracey L. Mccain,
Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec. -
Michael Landsittel,
CFO & Treasurer -
Daniel Lynch,
Independent Chairman of the Board -
Nicholas Lydon,
Independent Director -
Charles Rowland,
Independent Director -
George Demetri,
Independent Director -
Lonnel Coats,
Independent Director -
Lynn Seely,
Independent Director -
Mark Goldberg,
Independent Director -
Alexis Borisy,
Director -
Alexis A. Borisy A.M.,
Co-Founder & Director -
Fouad Namouni,
President, Research & Development -
Debra Durso-Bumpus,
Chief Human Resource Officer -
Kristin Hodous,
IR Contact Officer -
Ariel Hurley,
Vice President - Finance, Controller -
Dr. Percy H. Carter M.B.A., Ph.D.,
Chief Scientific Officer -
Dr. Christopher K. Murray,
Sr. VP of Technical Operations -
Ariel Hurley,
Principal Accounting Officer, VP of Fin. & Controller -
Debra Durso-Bumpus,
Chief People Officer -
Dr. Fouad Namouni,
Pres of R&D -
Mark J Levin,
10% owner -
Rock Ventures Ii, L.P.Third...,
-
Kevin P Starr,
10% owner -
Habib J Dable,
-
John Tsai,
-
Daniella Beckman,
-
Christoph Lengauer,
Chief Scientific Officer -
L. Becker Hewes,
CHIEF MEDICAL OFFICER -
Percy H. Carter,
CHIEF SCIENTIFIC OFFICER -
Therapeutics, Inc. Tango,
Director -
Kate Haviland,
CHIEF EXECUTIVE OFFICER -
Philina Lee,
CHIEF COMMERCIAL OFFICER